Veru reaches full enrollment for phase 2b quality clinical study of enobosarm for obesity and reports fiscal 2024 third quarter financial results

--phase 2b quality study of enobosarm in combination with semaglutide (wegovy®*) exceeds targeted full enrollment of >150 patients-- --topline data for primary endpoint of lean body mass expected january 2025--
VERU Ratings Summary
VERU Quant Ranking